Merck's Keytruda Conditionally Approved In Canada For Triple-Negative Breast Cancer

by Vandana Singh, Benzinga Editor

November 23, 2021 1:11 PM | 1 min read |

Health Canada has conditionally approved Merck & Co Inc's MRK Keytruda (pembrolizumab) for a form of breast cancer.
The approval covers adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease.
The conditional approval is based on Phase 3 KEYNOTE-355 trial results. Keytruda demonstrated improved progression-free survival (PFS) in combination with chemotherapy compared to chemotherapy alone.
Related Link: Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data.
Price Action: MRK shares are up 1.37% at $82.76 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Movers Trading Ideas General breast cancer Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.